La terapia dell'endometriosi. Nuove prospettive

Translated title of the contribution: The therapy of endometrioisis. New prospects

E. Somigliana, A. Chiodini, M. P. Odorizzi, F. Pompei, P. Viganò

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Surgery is still the first line of therapy for endometriosis. At present, medical therapy is mostly indicated for treatment and prevention of recurrences. Current pharmacological regimens induce a hypoestrogenic state; this effect tends, on one hand, to inhibit the growth of endometriotic implants while, on the other hand, it significantly interferes with the integrity of the hypothalamus-pituitary-ovarian axis. The aim of this study is to review current knowledge on the new experimental therapeutic approaches to the disease. English articles on this topic have been searched by Medline. A particular attention has been paid to experimental therapeutic interventions supported by in vivo results. Three different novel strategies have been identified: 1) To act on estrogenic dependence of endometriosis using new drugs such as aromatase inhibitors and raloxifene. These drugs may have the advantage to act more specifically on the disease. 2) To treat the disease with immuno-modulators and anti-inflammatory drugs. These compounds may be helpful in both limiting the growth of endometriotic implants and in controlling the symptoms of the disease. 3) To prevent adhesion reformation after surgical lysis. Adhesions are an important hallmark of endometriosis which cannot be adequately eliminated by surgery. The use of barrier and fluid agents after surgical lysis seems to be effective in this regard. Results from studies aimed to investigate the effectiveness of these approaches are appealing. However, controlled clinical trials are now required to appropriately determine their real benefits and their specific indications.

Original languageItalian
Pages (from-to)15-23
Number of pages9
JournalMinerva Ginecologica
Volume55
Issue number1
Publication statusPublished - Feb 2003

Fingerprint

Endometriosis
Pharmaceutical Preparations
Aromatase Inhibitors
Controlled Clinical Trials
Therapeutics
Growth
Hypothalamus
Anti-Inflammatory Agents
Pharmacology
Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Somigliana, E., Chiodini, A., Odorizzi, M. P., Pompei, F., & Viganò, P. (2003). La terapia dell'endometriosi. Nuove prospettive. Minerva Ginecologica, 55(1), 15-23.

La terapia dell'endometriosi. Nuove prospettive. / Somigliana, E.; Chiodini, A.; Odorizzi, M. P.; Pompei, F.; Viganò, P.

In: Minerva Ginecologica, Vol. 55, No. 1, 02.2003, p. 15-23.

Research output: Contribution to journalArticle

Somigliana, E, Chiodini, A, Odorizzi, MP, Pompei, F & Viganò, P 2003, 'La terapia dell'endometriosi. Nuove prospettive', Minerva Ginecologica, vol. 55, no. 1, pp. 15-23.
Somigliana E, Chiodini A, Odorizzi MP, Pompei F, Viganò P. La terapia dell'endometriosi. Nuove prospettive. Minerva Ginecologica. 2003 Feb;55(1):15-23.
Somigliana, E. ; Chiodini, A. ; Odorizzi, M. P. ; Pompei, F. ; Viganò, P. / La terapia dell'endometriosi. Nuove prospettive. In: Minerva Ginecologica. 2003 ; Vol. 55, No. 1. pp. 15-23.
@article{86ff8b595c834ebea0935d5bc1e973ba,
title = "La terapia dell'endometriosi. Nuove prospettive",
abstract = "Surgery is still the first line of therapy for endometriosis. At present, medical therapy is mostly indicated for treatment and prevention of recurrences. Current pharmacological regimens induce a hypoestrogenic state; this effect tends, on one hand, to inhibit the growth of endometriotic implants while, on the other hand, it significantly interferes with the integrity of the hypothalamus-pituitary-ovarian axis. The aim of this study is to review current knowledge on the new experimental therapeutic approaches to the disease. English articles on this topic have been searched by Medline. A particular attention has been paid to experimental therapeutic interventions supported by in vivo results. Three different novel strategies have been identified: 1) To act on estrogenic dependence of endometriosis using new drugs such as aromatase inhibitors and raloxifene. These drugs may have the advantage to act more specifically on the disease. 2) To treat the disease with immuno-modulators and anti-inflammatory drugs. These compounds may be helpful in both limiting the growth of endometriotic implants and in controlling the symptoms of the disease. 3) To prevent adhesion reformation after surgical lysis. Adhesions are an important hallmark of endometriosis which cannot be adequately eliminated by surgery. The use of barrier and fluid agents after surgical lysis seems to be effective in this regard. Results from studies aimed to investigate the effectiveness of these approaches are appealing. However, controlled clinical trials are now required to appropriately determine their real benefits and their specific indications.",
keywords = "Aromatase, Cell adhesion, Endometriosis, Enzyme inhibitors, Immune system, Raloxifene, Therapy",
author = "E. Somigliana and A. Chiodini and Odorizzi, {M. P.} and F. Pompei and P. Vigan{\`o}",
year = "2003",
month = "2",
language = "Italian",
volume = "55",
pages = "15--23",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - La terapia dell'endometriosi. Nuove prospettive

AU - Somigliana, E.

AU - Chiodini, A.

AU - Odorizzi, M. P.

AU - Pompei, F.

AU - Viganò, P.

PY - 2003/2

Y1 - 2003/2

N2 - Surgery is still the first line of therapy for endometriosis. At present, medical therapy is mostly indicated for treatment and prevention of recurrences. Current pharmacological regimens induce a hypoestrogenic state; this effect tends, on one hand, to inhibit the growth of endometriotic implants while, on the other hand, it significantly interferes with the integrity of the hypothalamus-pituitary-ovarian axis. The aim of this study is to review current knowledge on the new experimental therapeutic approaches to the disease. English articles on this topic have been searched by Medline. A particular attention has been paid to experimental therapeutic interventions supported by in vivo results. Three different novel strategies have been identified: 1) To act on estrogenic dependence of endometriosis using new drugs such as aromatase inhibitors and raloxifene. These drugs may have the advantage to act more specifically on the disease. 2) To treat the disease with immuno-modulators and anti-inflammatory drugs. These compounds may be helpful in both limiting the growth of endometriotic implants and in controlling the symptoms of the disease. 3) To prevent adhesion reformation after surgical lysis. Adhesions are an important hallmark of endometriosis which cannot be adequately eliminated by surgery. The use of barrier and fluid agents after surgical lysis seems to be effective in this regard. Results from studies aimed to investigate the effectiveness of these approaches are appealing. However, controlled clinical trials are now required to appropriately determine their real benefits and their specific indications.

AB - Surgery is still the first line of therapy for endometriosis. At present, medical therapy is mostly indicated for treatment and prevention of recurrences. Current pharmacological regimens induce a hypoestrogenic state; this effect tends, on one hand, to inhibit the growth of endometriotic implants while, on the other hand, it significantly interferes with the integrity of the hypothalamus-pituitary-ovarian axis. The aim of this study is to review current knowledge on the new experimental therapeutic approaches to the disease. English articles on this topic have been searched by Medline. A particular attention has been paid to experimental therapeutic interventions supported by in vivo results. Three different novel strategies have been identified: 1) To act on estrogenic dependence of endometriosis using new drugs such as aromatase inhibitors and raloxifene. These drugs may have the advantage to act more specifically on the disease. 2) To treat the disease with immuno-modulators and anti-inflammatory drugs. These compounds may be helpful in both limiting the growth of endometriotic implants and in controlling the symptoms of the disease. 3) To prevent adhesion reformation after surgical lysis. Adhesions are an important hallmark of endometriosis which cannot be adequately eliminated by surgery. The use of barrier and fluid agents after surgical lysis seems to be effective in this regard. Results from studies aimed to investigate the effectiveness of these approaches are appealing. However, controlled clinical trials are now required to appropriately determine their real benefits and their specific indications.

KW - Aromatase

KW - Cell adhesion

KW - Endometriosis

KW - Enzyme inhibitors

KW - Immune system

KW - Raloxifene

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0037318583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037318583&partnerID=8YFLogxK

M3 - Articolo

VL - 55

SP - 15

EP - 23

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 1

ER -